Business
Investors in drugmaker Mesoblast sweat on crucial capital raising – Sydney Morning Herald
The stem cell giant says it needs cash from its existing partnerships to ‘continue as a going concern’.
The ability of the group to continue as a going concern and realise its assets and discharge its liabilities in the normal course of business are dependent on cash inflows from successfully completing the private placement, as well as from existing strategic and financing partnerships, the auditors report said.
Analysts at Bell Potter noted last month that Mesoblasts balance sheet could come under pressure in the 2022 financial year if there were any hiccups with agreements and payments from partners…
-
General17 hours agoAs Iran-Australia relations plunge to a new low, Tehran faces another diplomatic setback
-
Noosa News13 hours agoBrisbane nation’s third-youngest capital; Leaders condemn anti-immigration rally
-
Noosa News22 hours agoQld nurses poised to strike deal with Crisafulli government
-
General19 hours agoUS CDC boss Susan Monarez refuses to quit, defying Trump’s White House